期刊文献+

C-erbB-2、p53、ER和PR受体在乳腺癌组织中的表达及意义 被引量:5

The expression of C-erbB-2,p53,ER and PR in breast carcinoma and their clinical significance
原文传递
导出
摘要 目的分析研究C-erbB-2、p53、ER、PR在乳腺癌中的表达与分期、转移关系及临床意义。方法用免疫组化法测定83例原发性乳腺癌C-erbB-2、p53、ER、PR的表达情况,进行对照比较。结果C-erbB-2、p53、ER、PR阳性表达者分别为30例(36.1%)、31例(37.3%)、45例(54.2%)、53例(63.9%)。C-erbB-2的表达与p53呈正相关(P<0.05),与ER、PR呈负相关(P<0.05)。C-erbB-2和p53的表达率随着临床分期增加和淋巴结转移而增加,差异有显著性(P<0.05)。ER、PR阳性表达率随着临床分期的递增和淋巴结转移的减少而降低,差异无显著性(P>0.05)。ER、PR阳性表达率与C-erbB-2、p53表达呈负相关,差异无显著性(P>0.05)。结论C-erbB-2、p53是判断乳腺癌预后的有效指标,ER、PR与临床分期及腋窝淋巴结转移有一定关系,联合检测C-erbB-2、p53、ER、PR可指导临床综合治疗。 Objective To study the expression of C-erbB-2, p53,ER and PR in breast carcinoma and their relationship with stages, metastasis and clinical significance. Methods The expression of C-erbB- 2, p53, ER and PR was examined with immunohistoehemical S-P technique in 83 cases of breast carcinoma.Results In 83 cases of breast carcinoma, the positive rate of C-erbB-2 was 36. 1% (30/80), p53 was 37. 3% (31/83) ,ER was 54. 2% (45/83) ans PR was 63.9% (53/83). The expression of C-erbB-2 was positively correlated with p53 ( P 〈0. 05 ) , and negatively correlated with ER and PR ( P 〈 0. 05 ). The expression rates of C-erbB-2 and p53 increased with increasing clinical stages and lymphatic metastasis, and there was significant difference ( P 〈 0. 05 ). The expression rates of ER and PR decreased with increasing clinical stages and decreasing lymphatic metastasis, with no significant difference ( P 〉 0. 05 ). The expression rates of ER and PR had negative correlation with the expression of C-erbB-2 and p53 and there was no significant difference(P 〉0. 05). Conclusions C-erbB-2 and p53 are useful prognostic factors in patients with breast carcinoma. The expression of ER and PR was associated with the clinical stage and lymphaticmetastasis of breast carcinoma. The combined detection of C-erbB-2, p53, ER and PR has important significance for clinical therapy.
出处 《中国肿瘤临床与康复》 2009年第2期105-107,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 乳腺肿瘤 免疫组织化学 C—erbB-2 P53 ER PR Breast neoplasms Immunohistochemistry C-erbB-2 p53 ER PR
  • 相关文献

参考文献5

二级参考文献42

  • 1[1]Giordano CH,Buzdar AU,Smith TL,et al.Is breast cancer survival improving? Cancer,2004,100:44
  • 2[2]Carey LA,Ewend MG,Metzger R,et al.Central nervous system metastases in women after multimodality therapy for high risk breast cancer.Breast Cancer Res Treat,2004,88:273
  • 3[3]Distefano A,Yong Yap Y,Hortobagyi GN,et al.The natural history of breast cancer patients with brain metastases.Cancer,1979,44:1913
  • 4[4]Tsukada Y,Fouad A,pickren JW,et al.Central nervous system metastasis from breast carcinoma.Autopsy study.Cancer,1983,52:2349
  • 5[5]Fokstuen T,Wilking N,Rutqvist LE,et al.Radiation therapy in the management of brain metastases from breast cancer.Breast Cancer Res Treat,2000,62:211
  • 6[6]Lederman G,Wronski M,Fine M.Fractionated radiosurgery for brain metastases in 43 patients with brain carcinoma.Breast Cancer Res Treat,2001.65:145
  • 7[7]Aronson SM,Gareis JH,Aronson BE.Metastatic noeplaslns of the brain.Cancer,1964,17:558
  • 8[8]Tham YL,Sexton K,Kramer R,et al.Primary breast cancer phenotypes associated with propensity for central nervous system metastases.Cancer,2006,107:696
  • 9[9]Gonzales-Angulo AM,Cristofanili M,Strom EA,et al.Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.Cancer,2004,101:1760
  • 10[10]Ryberg M,Nielson D,Osterlind K,et al.Predictor of central nervous system meastasis in patients with metastatic breast cancer:A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy.Breast Cancer Res Treat,2005,91:217

共引文献25

同被引文献113

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部